학술논문
Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection
Document Type
article
Author
Source
Thoracic Cancer, Vol 15, Iss 3, Pp 258-265 (2024)
Subject
Language
English
ISSN
1759-7714
1759-7706
1759-7706
Abstract
Abstract Background Associations between adjuvant chemotherapy (ACT) and the improvement in survival for patients with pT2N0M0 non‐small cell lung cancer (NSCLC) who received R0 resection remain controversial. This study aimed to evaluate the value of ACT for patients with pT2N0M0 NSCLCs, and to identify the subgroups who could benefit from ACT. Methods Multivariable Cox proportional hazards regression models were used to estimate independent prognostic factors. High‐risk factor (HRF) included visceral pleural invasion (VPI), lymphovascular invasion (LVI) and poor differentiation/undifferentiated tumors. Results Of the 899 patients, 277 (30.8%) patients received ACT. More younger patients (p